Greenland Mines Ltd

Company overview

• Name: Greenland Mines Ltd (GRML); formerly Klotho Neurosciences, Inc.
• Nasdaq ticker: GRML (Warrants: GRMLW)
• Core focus: development of medicines for chronic diseases, including oncology, cardiovascular, and neurodegenerative disorders.
• Platforms:
  • Generic drug portfolio
  • Biosimilar biologics platform (cancer-focused)
  • Proprietary gene therapy platform using Klotho (α-Klotho) for neurodegenerative diseases
• Recent corporate development: March 2026 acquisition of Greenland Mines Corp., expanding into development and mining of critical and precious minerals.

Product pipelines and programs

Gene therapy / α-Klotho platform

• Lead preclinical programs:
  • KLTO-101 (AAV9-CMV-sKL) — target: Alzheimer’s disease
  • KLTO-202 (AAVmyo-Des-sKL) — target: ALS
• Delivery technologies: AAV-based vectors (AAV9, AAVrh10, AAVmyo and modified capsids) and other delivery approaches, focused on CNS and neuromuscular targets.
• Intellectual property and licensing: exclusive worldwide licenses from Universitat Autònoma de Barcelona (UAB) and collaborators (UAB/ICREA; UAB/ICREA/CIBER/VHIR) covering s-Klotho diagnostics and therapeutics; collaboration with University of Heidelberg on modified AAV capsids.
• Patent portfolio: rights tied to US/EU/China patents and PCT filings (example: US 12,036,268 and related family).
• Clinical development status: preclinical with plans to pursue IND submissions and early human studies; KLTO-202 IND planned for ALS following completion of animal toxicology.

Biosimilars and generics

• Products covered: rituximab (Rituxan/Mabthera), bevacizumab (Avastin), and cetuximab (Erbitux) added via amendments.
• Licensee/partner: Reliance Life Sciences (RLS).
• Territory: exclusive rights in North America, Europe, and Israel for the initial biosimilar program.
• Economics: 5% royalty on Net Sales; upfront fees and milestone payments; product-specific term of 10 years with automatic extension for an additional 10 years unless notice is given.
• Regulatory pathway: development under FDA and EMA biosimilar frameworks with potential pursuit of interchangeability where appropriate.

Market-ready acquisitions

• September 12, 2022: acquisition of five market-approved anti-cancer drugs in Germany used in FOLFOX/FOLFIRI regimens and other indications, expanding the oncology portfolio with marketed authorizations.

Research and collaboration

• Sponsored Research Agreement with UAB (January 24, 2022): two-year budget of €623,100.
• Ongoing collaboration discussions and opportunities for licensing or partnerships; company may sell or out-license certain technologies.

Intellectual property and licenses

UAB agreement (KLTO-101)

• Exclusive worldwide license; royalty-bearing.
• Royalty: 3% of Net Sales where patent rights exist (1.5% in some cases).
• Milestones: IND €35,000; Phase 1 €250,000; Phase 2 €500,000; Phase 3 €1,200,000; first commercial sale €2,000,000.
• Term: royalties payable until last-to-expire patent in each country.

UAB/ICREA/CIBER/VHIR agreement (KLTO-202)

• Exclusive worldwide license; royalty-bearing.
• Royalty and milestone structure similar to KLTO-101.
• Includes anti-stacking clause and royalty coordination to avoid duplicate payments when patents overlap.

University of Heidelberg license (modified AAV capsids)

• Royalty: 2% of Net Sales.
• Milestones: €150,000 on execution; €150,000 within 60 days of Phase 1 start; €200,000 within 60 days of Phase 3 start.

Reliance Life Sciences biosimilar license (RLS)

• Exclusive license covering North America, Europe, and Israel.
• Upfront: $300,000 initial; $150,000 subsequent for added cetuximab rights.
• Royalty: 5% of Net Sales, plus milestone payments tied to regulatory approvals and sales-based milestones up to $10 million.
• Sublicense rights available with alternative sublicense milestone arrangements.

Regulatory and compliance considerations

• IPR protections, patent term considerations, and ongoing maintenance responsibilities are central to program economics and freedom to operate.
• Rights to sublicense exist under several agreements and are subject to milestone and royalty frameworks.

Employees, facilities, and operations

• Employees (as of March 30, 2026): 2 full-time employees; 3 additional employees based in Europe following the Greenland Mines Corp. acquisition; additional consultants engaged as needed.
• Offices:
  • Two small offices in Charlotte, NC and Omaha, NE (~400 sq ft each).
  • Omaha office provided rent-free by the CEO.
  • Charlotte office rent: $700/month ($8,400/year).
• Principal executive office: 1300 South Boulevard, Suite D, Charlotte, NC 28203.

Financial status and revenue

• Revenue: the company has not generated product revenue to date.
• Profitability: the company has incurred historical losses and expects to incur losses for the foreseeable future.
• Funding: the company states it requires substantial additional funding to advance development and regulatory programs.
• Dividends: no dividends paid to date; the company intends to retain earnings to support operations.
• Financial outlook: progression of programs depends on external financing, partnerships or licensing, and may result in equity or debt financing and associated dilution.

Markets, commercialization, and competition

• Commercial strategy: emphasis on out-licensing and partnerships for ex-U.S. markets, with potential internal commercialization in the U.S. for select programs if developed.
• Competitive landscape:
  • Biosimilars: competition in bevacizumab and rituximab markets.
  • Gene therapy: s-Klotho gene therapy currently does not have established direct competitors; it will operate within a broader, competitive gene-therapy landscape.

Regulatory and risk context

• Gene therapy: programs are at preclinical stage; development will require regulatory and safety studies, including toxicology and IND-enabling work.
• Biosimilars: regulatory pathways under FDA and EMA frameworks require comparative analytical, preclinical, and clinical data; interchangeability and market acceptance are key considerations.
• General regulatory risks: compliance with FDA/EMA and other regulatory requirements, potential delays, costs, and penalties are material development risks.

Scope summary

• Greenland Mines Ltd operates across multiple platforms (gene therapy, biosimilars/generics, and oncology drugs via acquisitions) and maintains a portfolio of licenses, milestones, and royalties.
• No products are approved or marketed; the company is focused on development, collaborations, and potential licensing or out-licensing arrangements to advance its programs.